Octavio Espinoza | executive |
Todd Davis | executive |
Paul Hadden | executive |
Karen Reeves | executive |
Matthew Hewitt | analyst |
Douglas Miehm | analyst |
Lawrence Solow | analyst |
Thank you for standing by. My name is Pam, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand Second Quarter 2024 Earnings Webcast. [Operator Instructions] I would now like to turn the conference over to Tavo Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals Inc.
You may begin.